Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 2:17:545-561.
doi: 10.2147/DMSO.S448476. eCollection 2024.

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Omar E Hegazi  1   2 , Samer O Alalalmeh  1   2 , Moyad Shahwan  1   2 , Ammar Abdulrahman Jairoun  3   4 , Mansour M Alourfi  5   6 , Ghfran Abdulrahman Bokhari  6 , Abdullah Alkhattabi  6 , Saeed Alsharif  7 , Mohannad Abdulrahman Aljehani  8 , Abdulmalik Mohammed Alsabban  9 , Mohammad Almtrafi  9 , Ysear Abdulaziz Zakri  9 , Abdullah AlMahmoud  10 , Khalid Mohammed Alghamdi  10 , Ahmed M Ashour  11 , Nasser M Alorfi  11
Affiliations
Review

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Omar E Hegazi et al. Diabetes Metab Syndr Obes. .

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD.

Methods: The terms "Non-alcoholic Fatty Liver Disease" and "NAFLD" were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review.

Results: The ClinicalTrials.gov database was searched for trials examining pharmacotherapeutics in NAFLD. The search revealed 1364 trials, with 31 meeting the inclusion criteria. Out of these, 19 were finalized for evaluation. The dominant intervention model was Parallel. The most prevalent studies were in Korea (26.3%) and China (21.1%). The most common intervention was metformin (12.1%), with others like Exenatide and Pioglitazone accounting for 9.1%.

Conclusion: Therapeutics used to manage NAFLD are limited. However, various medications offer potential benefits. Further investigations are definitely warranted.

Keywords: NAFLD; clinical trials; hepatology; metabolic disorder; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of trial selection process.
See this image and copyright information in PMC

References

    1. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med. 2018;18(3):245–250. doi:10.7861/clinmedicine.18-3-245 - DOI - PMC - PubMed
    1. Shahwan M, Jairoun AA, Alaila RFF, et al. Relation of erythrocyte sedimentation rate, glycemic parameters and lipid profile for the prediction of major adverse cardiovascular events: a single-center, cross-sectional study in Palestine. Obes Med. 2023;43:100513. doi:10.1016/j.obmed.2023.100513 - DOI
    1. Marchisello S, Di Pino A, Scicali R, et al. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview. Int J Mol Sci. 2019;20(8):1948. doi:10.3390/ijms20081948 - DOI - PMC - PubMed
    1. Role of insulin resistance in nonalcoholic fatty liver disease | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic. Available from: https://academic.oup.com/jcem/article/91/12/4753/2656230. Accessed August 24, 2023.
    1. Hegazi OE, Alalalmeh SO, Alnuaimi GRH, et al. NAFLD and nutraceuticals: a review of completed Phase III and IV clinical trials. Front Med. 2023;1:10. - PMC - PubMed